Powered by

-Novartis Kisqali receives the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale

Sep 21, 2020 - ENP Newswire

Basel - Novartis proudly announces that Kisqali has achieved a score of five out of five on the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) for first-line premenopausal patients with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer1.

This perfect score was achieved as a result of the significant overall survival benefit and the quality of life improvements demonstra...